Wednesday, October 1, 2014

Anthera Pharmaceuticals (ANTH) provides update on partner discussions for lead compound

Anthera (ANTH) announced after the bell that they are in partnership discussions for its lead compound Blisibimod.  Blisibimod is a potential treatment for Lupus and IgA nephropathy and the company said the discussions were specifically related to partnerships for the compound outside of the United States.  This is a very positive development as a partnership with a reputable partner would show that due diligence was done on both the prospects of the compound and the credibility of the leadership team and company.  Anthera has a mere market cap of $40 million with a Phase 3 drug to treat an indication that desperately needs improved options - Lupus.  This tells me one thing - no one believes in the compound or the company.  Firming up a solid partner would help alleviate these concerns and could send the stock much higher.

I currently own 6,000 shares of Anthera but probably won't add to his position until this story plays out.


No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com